Viatris agrees to buy Pacira BioSciences for $36.50 a share in cash, valuing deal at $1.65 billion
Bitget2026/10/08 11:45Viatris agreed to buy Pacira for USD 36.50 per share in cash, valuing the equity at about USD 1.65 billion. Pacira’s portfolio includes EXPAREL and ZILRETTA, positioning Viatris to scale in non-opioid pain therapies. Pacira generated about USD 746 million revenue and USD 177 million adjusted EBITDA for the 12 months ended June 30, 2026. Funding planned mainly from excess cash, with the balance from short-term borrowings; Viatris expects minimal impact on leverage. Closing targeted by end-2026; Pacira would become a wholly owned subsidiary and its Nasdaq listing would end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610080745PR_NEWS_USPR_____NE66710) on October 08, 2026, and is solely responsible for the information contained therein.
- Viatris agreed to buy Pacira for USD 36.50 per share in cash, valuing the equity at about USD 1.65 billion.
- Pacira’s portfolio includes EXPAREL and ZILRETTA, positioning Viatris to scale in non-opioid pain therapies.
- Pacira generated about USD 746 million revenue and USD 177 million adjusted EBITDA for the 12 months ended June 30, 2026.
- Funding planned mainly from excess cash, with the balance from short-term borrowings; Viatris expects minimal impact on leverage.
- Closing targeted by end-2026; Pacira would become a wholly owned subsidiary and its Nasdaq listing would end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
